Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03905135
Title Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

anaplastic large cell lymphoma

mycosis fungoides

peripheral T-cell lymphoma

Therapies

Avelumab + rhIL-15

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST